The IPO may value the company at C$1 billion or more, according to the people, who spoke on condition they not be identified ...

The IPO of Niva Bupa Health Insurance Company includes a fresh share sale of Rs 800 crore and an offer-for-sale (OFS) of up to 1,400 crore by its promoter entities amounting to Rs 1,400 crore.

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest biotechs to list on the Nasdaq. Upstream had previously expected to ...

Ceribell rang in a $180.3 million IPO last week, with its public debut on the Nasdaq coming in well above its first pricing goal of about $101 million and its stock price trading up about 47% ...

But the filing to go public reveals that Pony’s board of directors recently slashed the minimum valuation for its IPO down to $4 billion. Pony also dropped its minimum target for what it wants ...

The U.S. IPO market maintains its steady pace, with a fresh set of companies looking to raise capital. With the recent better-than-expected U.S. September report on job additions signalling a ...

KinderCare Learning Companies (KLC) opened for trading at $27.00 after pricing its IPO at $24 per share, which was on the low end of the expected range of $24 to $27. Shares of KinderCare (KLC ...

Mint is India’s No.1 choice for IPO coverage and analysis (Source: Similarweb, FY-24). You can access on this page everything you need to know about IPOs - from latest news, issues dates ...

Tennet Is Said to Select Banks for IPO of German Operations ABN Amro, Deutsche Bank, Goldman, Morgan Stanley are selected A stake sale in the German unit could still be an option ...

The IPO of 24,000,000 shares of KinderCare’s common stock was priced at $24.00 per share on 8 October. The market cap was around $3 billion at close yesterday. Partners will hold around 71 ...

Guardian Pharmacy is an example of growing business opportunities created by a growing senior population. Guardian Pharmacy raised $112 million in its initial public offering late last month ...

Rivus Pharmaceuticals Inc., a drug developer focused on obesity treatments, is considering a US initial public offering as soon as 2024, according to people with knowledge of the matter.